ArticleJCO precision oncology2021
Distribution of Genomic Testing Resources by Oncology Practice and Rurality: A Nationally Representative Study.
Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review.Journal of the National Cancer Institute · 2024Pooled it
- Application of a concise video to improve patient understanding of tumor genomic testing in community and academic practice settings.PloS one · 2026Trial
- Knowledge, Attitudes, and Perceived Barriers to Genetics and Precision Medicine Among Rural Participants in a Large Academic Biobank: A Mixed-Methods Study.Journal of personalized medicine · 2026Article
- Leveraging Pharmacy Education through a Train-the-Trainer Model to Enhance Breast Cancer Literacy in Rural Communities.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Commercial price variation in precision oncology testing across US hospitals.Health affairs scholar · 2026Article
- An automated plasma-based proteotyping immunoassay for APOE ε4 zygosity classification in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Beliefs and perceptions of genetic testing by clinical, demographic, and health characteristics: A U.S.-based study utilizing the health information national trends (HINTS) survey.Preventive medicine reports · 2025Article
- Bridging the gap: ctDNA, genomics, and equity in breast cancer care.NPJ breast cancer · 2025Review
- Revolutionizing Cancer Registries: The Promise and Challenges of Integrating Molecular Markers for Enhanced Patient Care and Research.Journal of registry management · 2025Article
- Urban and Rural Differences in Cancer Treatment Disruption Among Patients With COVID-19: An Analysis of the US ASCO COVID-19 in Oncology Registry.Cancer medicine · 2025Article
- Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake.Cancer · 2024Article
- Widespread Adoption of Precision Anticancer Therapies After Implementation of Pathologist-Directed Comprehensive Genomic Profiling Across a Large US Health System.JCO oncology practice · 2024Article
- Socioeconomic and urban-rural disparities in genome-matched treatment receipt and survival after genomic tumor testing.JNCI cancer spectrum · 2024Article
- Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Area-based disparities in non-small-cell lung cancer survival.Acta oncologica (Stockholm, Sweden) · 2024Article
- Importance of Patient Health Insurance Coverage and Out-of-Pocket Costs for Genomic Testing in Oncologists' Treatment Decisions.JCO oncology practice · 2024Article
- Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience.The oncologist · 2024Article
- Molecular diagnostics tailoring personalized cancer therapy-an oncologist's view.Virchows Archiv : an international journal of pathology · 2024Review
- Clinical Network Systems Biology: Traversing the Cancer Multiverse.Journal of clinical medicine · 2023Review
- The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State.JCO precision oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeOncologists are increasingly using molecular profiling to inform personalized patient treatment decisions. Despite its promising utility, the integration of genomic testing into diverse clinical health care settings across geographic settings has been understudied.
methodsWe used data from the National Survey of Precision Medicine in Cancer Treatment, a nationally representative sample of practicing US oncologists, to assess the availability of six genomic testing resources, including on-site pathology, contracts with outside laboratories, on-site genetic counselors, internal policies or protocols for using genomic and biomarker testing, electronic medical record alerts, and genomic or molecular tumor boards. We used multivariate logistic regression models to examine differences in the availability of each genomic testing resource by practice type and rurality while adjusting for payer mix and patient volume.
resultsA larger proportion of multispecialty group and academic practices had genomic testing resources available compared with solo and nonacademic practices. Electronic medical record alerts were the least available resource, whereas contracts with outside laboratories were the most available resource. Compared with urban practices, there were significantly fewer practices located in rural areas that had on-site pathology, on-site genetic counselors, protocols for genomic tests, and molecular tumor boards.
conclusionGenomic testing resources varied by practice type and geography among a nationally representative sample of practicing oncologists. This variation has important implications for the development of interventions and policies to support the more equitable delivery of precision oncology to patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.